The American journal of gastroenterology · 2025
Delayed Remission With Advanced Therapies Is Not Associated With Worse 1-Year Outcomes in Inflammatory Bowel Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghoneim Sara, Choe Heather, Boneschansker Leo, Sachdeva Karan, Lau Helena, Xavier Ramnik, Ananthakrishnan Ashwin N
Аннотация
INTRODUCTION: In randomized trials, early improvement with biologic therapy in Crohn's disease (CD) and ulcerative colitis (UC) is linked to better long-term outcomes. However, some patients may respond later (late remitters). The frequency of such late remitters, predictors of who may belong to this group, and the long-term outcome of such patients have not been examined robustly.
METHODS: This prospective single-center study enrolled patients with moderate-to-severe CD or UC initiating biologic or small molecule therapy. Disease activity was assessed prospectively using Harvey Bradshaw Index (CD) and Simple Clinical Colitis Activity Index (UC). Patients were followed for 1 year. Early remitters achieved clinical remission (Harvey-Bradshaw Index ≤4, Simple Clinical Colitis Activity Index ≤2) by week 14. Late remitters did not achieve remission by week 14 but attained remission by week 30. Nonremitters failed to achieve remission by week 30.
RESULTS: Our cohort included 596 patients (280 CD, 316 UC) initiating anti-tumor necrosis factor (n = 174), vedolizumab (n = 171), anti-interleukin (primarily ustekinumab, n = 116), or Janus kinase inhibitors (primarily tofacitinib, n = 135). Most (89%) had previous biologic exposure. Clinical remission at week 14 occurred in 37%; an additional 14% achieved remission between weeks 14 and 30 (late remitters). Late remitters had slightly shorter disease duration but comparable demographics and disease characteristics to early responders. Late remitters had similar rates of clinical (64% vs 63%) and endoscopic remission (43% vs 49%) at week 52 compared with early remitters, with superior outcomes compared with nonremitters (13% and 16%, respectively; P < 0.001).
DISCUSSION: Approximately one-sixth of patients achieved delayed remission by week 30. They had comparable 1-year outcomes as early remitters. Identifying predictors of delayed remission could help prevent early therapy discontinuation without affecting long-term outcomes.
METHODS: This prospective single-center study enrolled patients with moderate-to-severe CD or UC initiating biologic or small molecule therapy. Disease activity was assessed prospectively using Harvey Bradshaw Index (CD) and Simple Clinical Colitis Activity Index (UC). Patients were followed for 1 year. Early remitters achieved clinical remission (Harvey-Bradshaw Index ≤4, Simple Clinical Colitis Activity Index ≤2) by week 14. Late remitters did not achieve remission by week 14 but attained remission by week 30. Nonremitters failed to achieve remission by week 30.
RESULTS: Our cohort included 596 patients (280 CD, 316 UC) initiating anti-tumor necrosis factor (n = 174), vedolizumab (n = 171), anti-interleukin (primarily ustekinumab, n = 116), or Janus kinase inhibitors (primarily tofacitinib, n = 135). Most (89%) had previous biologic exposure. Clinical remission at week 14 occurred in 37%; an additional 14% achieved remission between weeks 14 and 30 (late remitters). Late remitters had slightly shorter disease duration but comparable demographics and disease characteristics to early responders. Late remitters had similar rates of clinical (64% vs 63%) and endoscopic remission (43% vs 49%) at week 52 compared with early remitters, with superior outcomes compared with nonremitters (13% and 16%, respectively; P < 0.001).
DISCUSSION: Approximately one-sixth of patients achieved delayed remission by week 30. They had comparable 1-year outcomes as early remitters. Identifying predictors of delayed remission could help prevent early therapy discontinuation without affecting long-term outcomes.
Предметные рубрики MeSH
HumansFemaleMaleRemission InductionAdultProspective StudiesColitis, UlcerativeSeverity of Illness IndexTreatment OutcomeInfliximabAntibodies, Monoclonal, HumanizedMiddle AgedCrohn DiseaseGastrointestinal AgentsPiperidinesTime FactorsAdalimumabUstekinumabTreatment DelayTumor Necrosis Factor-alphaJanus Kinase InhibitorsPyrimidines